Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis
26 sept. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Study met both co-primary endpoints and all secondary endpointsAt week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared...
New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
09 sept. 2022 08h15 HE
|
Arcutis Biotherapeutics, Inc.
Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle...
Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
28 sept. 2021 16h05 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...